Clinical Trial

A Study of SRSD216 in Patients With Elevated Lipoprotein (a)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 6, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD216 and to identify a dose range for further studies in subjects with elevated Lp(a) level with or without ASCVD history.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-10.
Trial Details
NCT Number NCT07172646
Lead Sponsor Sirius Therapeutics Co., Ltd.
Conditions Hyperlipoproteinemia (a)
Enrollment 84 participants
Start Date 2025-04-07
Primary Completion 2026-05 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-06